Biblio Discovery — Demo Discovery Service

7 hasil untuk "1"

Menampilkan 1–7 · 0,33 detik · RSS

  1. Artikel Jurnal Teks lengkap

    Possibilities and limitations of antisense oligonucleotide therapies for the treatment of monogenic disorders

    Marlen C. Lauffer; Willeke van Roon‐Mom; Annemieke M Aartsma-Rus dkk.

    Communications Medicine · 2024 · Inggris · OpenAlex Scopus

    Antisense oligonucleotides (ASOs) are incredibly versatile molecules that can be designed to specifically target and modify RNA transcripts to slow down or halt rare genetic disease progression. They offer the potential to target groups of patients or can be tailored for individual cases…

  2. Artikel Jurnal

    Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension

    John P.H. Wilding; Rachel Louise Batterham; Melanie Jane Davies dkk.

    Diabetes Obesity and Metabolism · 2022 · Inggris · OpenAlex Scopus

    AIM: To explore changes in body weight and cardiometabolic risk factors after treatment withdrawal in the STEP 1 trial extension. MATERIALS AND METHODS: with ≥ 1 weight-related co-morbidity) without diabetes to 68 weeks of once-weekly subcutaneous semaglutide 2.4 mg (including 16 weeks of dose…

  3. Artikel Jurnal Teks lengkap

    Screening for Type 1 Diabetes in the General Population: A Status Report and Perspective

    Emily K. Sims; Rachel E.J. Besser; Colin Mark Dayan dkk.

    Diabetes · 2022 · Inggris · OpenAlex Scopus

    Most screening programs to identify individuals at risk for type 1 diabetes have targeted relatives of people living with the disease to improve yield and feasibility. However, ∼90% of those who develop type 1 diabetes do not have a family history. Recent successes in disease-modifying therapies to…

Dari koleksi institusi

Perpustakaan Kampus · 2 judul cetakLihat semua
  1. Artikel Jurnal Teks lengkap

    Tralokinumab for moderate‐to‐severe atopic dermatitis: results from two 52‐week, randomized, double‐blind, multicentre, placebo‐controlled phase III trials (ECZTRA 1 and ECZTRA 2)*

    Andreas Wollenberg; Andrew Blauvelt; Emma Guttman‐Yassky dkk.

    British Journal of Dermatology · 2020 · Inggris · OpenAlex Scopus

    BACKGROUND: Tralokinumab, a fully human monoclonal antibody, specifically neutralizes interleukin-13, a key cytokine driving peripheral inflammation in atopic dermatitis (AD). In phase II studies, tralokinumab combined with topical corticosteroids provided early and sustained improvements in AD…

  2. Artikel Jurnal Teks lengkap

    Teplizumab improves and stabilizes beta cell function in antibody-positive high-risk individuals

    Emily K. Sims; Brian N. Bundy; Kenneth Stier dkk.

    Science Translational Medicine · 2021 · Inggris · OpenAlex Scopus

    T cell subsets indicated that partially exhausted effector cells were associated with clinical response. Thus, this trial showed improvement in metabolic responses and delay of diabetes with immune therapy.

  3. Artikel Jurnal Teks lengkap

    Convalescent plasma for hospitalized patients with COVID-19: an open-label, randomized controlled trial

    Philippe Bégin; Jeannie Callum; Erin Jamula dkk.

    Nature Medicine · 2021 · Inggris · OpenAlex Scopus

    The efficacy of convalescent plasma for coronavirus disease 2019 (COVID-19) is unclear. Although most randomized controlled trials have shown negative results, uncontrolled studies have suggested that the antibody content could influence patient outcomes. We conducted an open-label, randomized…